- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07910006
Multimodal Assessment of Neuromuscular Electrical Stimulation (NMES) Effects on Respiratory and Peripheral Muscles in Chronic Obstructive Pulmonary Disease (COPD) (NMES in COPD)
Comparative Effects of Targeted Neuromuscular Electrical Stimulation (NMES) on Respiratory and Peripheral Muscles in Patients With Chronic Obstructive Pulmonary Disease (COPD): A Multimodal Assesment Using Diaphragm Ultrasound and Plasma Biomarkers (Interleukin-6 and Insulin-like Growth Factor- 1)
The goal of this clinical trial is to learn if targeted neuromuscular electrical stimulation (NMES) can treat respiratory and peripheral muscle weakness in patients with chronic obstructive pulmonary disease (COPD). The main questions it aims to answer are:
- Does targeted NMES improve diaphragm thickening fraction and excursion as measured by diaphragm ultrasound?
- What are the comparative effects of targeted NMES on plasma biomarkers, specifically Interleukin-6 (IL-6) and Insulin-like Growth Factor-1 (IGF-1)? Researchers will compare three groups: the first intervention group receiving intercostal NMES combined with Pursed-Lip Breathing (PLB), the second intervention group receiving quadriceps NMES combined with PLB, and a control group receiving sham upper trapezius NMES combined with PLB, to see if targeted NMES provides superior improvements in respiratory and peripheral muscle function.
Participants will:
- Undergo baseline screening, including a diaphragm ultrasound and a blood draw for plasma biomarkers (IL-6 and IGF-1)
- Be randomly assigned to one of the three groups to receive either intercostal NMES, quadriceps NMES, or sham upper trapezius NMES, all combined with Pursed-Lip Breathing exercises
- Complete a post-intervention assessment involving repeat ultrasound imaging and biomarker analysis to evaluate muscle and systemic changes
Study Overview
Status
Conditions
Detailed Description
Chronic Obstructive Pulmonary Disease (COPD) is characterized by chronic airflow limitation and progressive respiratory and peripheral muscle dysfunction. While pulmonary rehabilitation is a cornerstone of management, severe breathlessness often limits a patient's exercise tolerance. Neuromuscular Electrical Stimulation (NMES) offers an alternative modality to train specific muscle groups without inducing severe dyspnea. However, the comparative efficacy of stimulating respiratory muscles versus peripheral muscle groups requires deeper investigation using precise physiological and biochemical markers.
This study utilizes a three-arm randomized controlled design to evaluate and compare the localized and systemic effects of targeted NMES. The mechanical properties of the respiratory system will be monitored using diaphragm ultrasound, focusing on active contractility and movement. Concurrently, systemic inflammation and muscle anabolic responses will be analyzed through plasma biomarkers to understand the underlying biomolecular pathways.
Upon meeting the eligibility criteria and providing written informed consent, the 45 participants will be randomly assigned to one of three study arms in a 1:1:1 ratio. All participants will undergo a standardized baseline assessment. Following the allocation, each group will complete their designated 8-week intervention protocol consisting of 3 sessions per week (total of 24 sessions) concurrently with Pursed-Lip Breathing (PLB) training. A comprehensive post-intervention reassessment will be conducted immediately following the final session to determine the comparative physiological and biochemical outcomes.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Dian Marta Sari, Physiatrist
- Phone Number: +62 812 2181 227
- Email: dian.marta@unpad.ac.id
Study Locations
-
-
West Java
-
Bandung, West Java, Indonesia
- Recruiting
- Faculty of Medicine Universitas Padjadjaran
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients diagnosed with stable Chronic Obstructive Pulmonary Disease (COPD), GOLD spirometric grade 2-4 (post-bronchodilator FEV1/FVC <0.70 with FEV1 <80% predicted), confirmed by a pulmonologist.
- Age ≥ 40 years old.
- Willing to participate in the study and sign the written informed consent form.
Exclusion Criteria:
- Recent thoracic or abdominal surgery, pneumothorax, or a history of spontaneous pneumothorax.
- Participation in other structured respiratory muscle training or pulmonary rehabilitation programs that may confound the study results.
- Presence of neuromuscular, bulbar, laryngeal, or other disorders that may independently impair respiratory muscle function.
- Use of a cardiac pacemaker or any metal/electronic implant at the intended stimulation area.
- Diagnosis of heart failure classified as NYHA (New York Heart Association) class III-IV.
- Presence of skin lesions, open wounds, or active dermatitis in the intended electrode placement areas.
- Current use of systemic (oral) corticosteroids or history of use within 4 weeks prior to enrollment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intercostal NMES + PLB
Participants receive targeted NMES to the intercostal muscles combined with Pursed-Lip Breathing (PLB) exercises. The protocol is administered 3 times per week for 8 weeks. |
Intercostal Neuromuscular Electrical Stimulation (NMES) is a procedure that uses small electrical impulses delivered through electrodes on the skin to stimulate motor nerves and cause passive muscle contractions which will be applied to the intercostal muscles Pursed-lip breathing is a simple respiratory exercise that involves inhaling slowly through your nose and exhaling gently through tightly puckered or "pursed" lips (as if whistling or blowing out a candle). |
|
Experimental: Quadriceps NMES + PLB
Participants receive targeted NMES to the quadriceps muscles combined with Pursed-Lip Breathing (PLB) exercises. The protocol is administered 3 times per week for 8 weeks. |
Pursed-lip breathing is a simple respiratory exercise that involves inhaling slowly through your nose and exhaling gently through tightly puckered or "pursed" lips (as if whistling or blowing out a candle). Quadriceps Neuromuscular Electrical Stimulation (NMES) is a procedure that uses small electrical impulses delivered through electrodes on the skin to stimulate motor nerves and cause passive muscle contractions which will be applied to the quadriceps muscles |
|
Placebo Comparator: Sham NMES + PLB
Participants receive sham NMES to the upper trapezius muscles combined with Pursed-Lip Breathing (PLB) exercises. The protocol is administered 3 times per week for 8 weeks. |
Pursed-lip breathing is a simple respiratory exercise that involves inhaling slowly through your nose and exhaling gently through tightly puckered or "pursed" lips (as if whistling or blowing out a candle). Sham Neuromuscular Electrical Stimulation (NMES) is a control procedure that delivers minimal electrical impulses via transcutaneous skin patches to the upper trapezius muscles, generating only a mild tingling sensation as a placebo effect without triggering any passive muscle contractions. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diaphragm Excursion (DE)
Time Frame: Baseline (Week 0) and post-intervention (Week 8)
|
Measured via B-mode or M-mode transabdominal ultrasound during quiet and deep breathing to evaluate the distance the diaphragm travels vertically. A higher excursion value indicates better diaphragmatic mobility. |
Baseline (Week 0) and post-intervention (Week 8)
|
|
Diaphragm Thickening Fraction (TF)
Time Frame: Baseline (Week 0) and post-intervention (Week 8)
|
Calculated using the formula: [(Thickness at end-inspiration - Thickness at end-expiration) / Thickness at end-expiration] x 100%. Measured via high-frequency linear ultrasound at the zone of apposition to assess diaphragmatic contractile function. |
Baseline (Week 0) and post-intervention (Week 8)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Plasma Interleukin-6 (IL-6) Levels
Time Frame: Baseline (Week 0) and post-intervention (Week 8)
|
Measured via Enzyme-Linked Immunosorbent Assay (ELISA) from venous blood samples to evaluate systemic inflammatory profiles. Decreased levels indicate a reduction in systemic inflammation. |
Baseline (Week 0) and post-intervention (Week 8)
|
|
Change in Plasma Insulin-like Growth Factor-1 (IGF-1) Levels
Time Frame: Baseline (Week 0) and post-intervention (Week 8)
|
Measured via Enzyme-Linked Immunosorbent Assay (ELISA) from venous blood samples to evaluate muscle anabolic activity and systemic growth factor response. Increased levels indicate an improved anabolic state. |
Baseline (Week 0) and post-intervention (Week 8)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Six-Minute Walk Test (6MWT) Distance
Time Frame: Baseline (Week 0) and post-intervention (Week 8)
|
Measured by the total distance in meters that a participant can walk quickly on a flat, hard surface in a period of 6 minutes. It evaluates functional exercise capacity. |
Baseline (Week 0) and post-intervention (Week 8)
|
|
Modified Medical Research Council (mMRC) Dyspnea Scale
Time Frame: Baseline (Week 0) and post-intervention (Week 8)
|
A questionnaire used to rate the baseline dyspnea (breathlessness) on a scale from 0 (breathless only with strenuous exercise) to 4 (too breathless to leave the house). Lower scores indicate less respiratory disability. |
Baseline (Week 0) and post-intervention (Week 8)
|
|
COPD Assessment Test (CAT) Score
Time Frame: Baseline (Week 0) and post-intervention (Week 8)
|
An 8-item questionnaire measuring the health status impairment in COPD patients. Scores range from 0 to 40, where higher scores signify a worse health status and severe impact of COPD on the patient's life. |
Baseline (Week 0) and post-intervention (Week 8)
|
|
Modified Borg Scale (MBS) for Dyspnea
Time Frame: Baseline (Week 0) and post-intervention (Week 8)
|
A categorical scale ranging from 0 (no breathlessness at all) to 10 (maximal breathlessness) used to assess the patient's perceived level of shortness of breath during functional activity or rest. |
Baseline (Week 0) and post-intervention (Week 8)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neurologic Manifestations
- Musculoskeletal Diseases
- Nervous System Diseases
- Muscular Diseases
- Neuromuscular Manifestations
- Pathologic Processes
- Chronic Disease
- Disease Attributes
- Respiratory Tract Diseases
- Lung Diseases
- Lung Diseases, Obstructive
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Pulmonary Disease, Chronic Obstructive
- Muscle Weakness
Other Study ID Numbers
- IKFR-202609.01
- 004/PEG-PRJ/SL/UKM/X/2026 (Other Grant/Funding Number: Maranatha Christian University)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Individual participant data will not be made publicly available to protect participant privacy
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.